Business Context and Reporting Period
Alnylam Pharmaceuticals, Inc. filed a Form 8-K on January 10, 2022, reporting preliminary financial results for the fourth quarter and full year ended December 31, 2021. The company focuses on RNAi therapeutics, specifically highlighting revenues from ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran).
Key Financial Metrics
- Revenue: Preliminary global net product revenues for Q4 2021 were approximately $199 million. Full-year 2021 revenues were approximately $662 million.
- Liquidity: As of December 31, 2021, the company held preliminary cash, cash equivalents, and marketable securities of approximately $2.4 billion.
- Profit, Margins, and Debt: The filing text does not provide clear values for net income, operating margins, or total debt.
Material Changes and Updates
The filing provides updated commercial launch information for the company's three primary products. The reported revenue figures represent a preliminary update ahead of the complete financial results announcement scheduled for February 2022. No specific prior period comparison data is included in this text to quantify year-over-year growth rates.
Guidance, Outlook, and Risks
Management updated its cash guidance, confirming the $2.4 billion liquidity position at year-end. The company noted that the preliminary selected financial results are unaudited and subject to adjustment. The filing explicitly states that the information is furnished and not "filed" for purposes of Section 18 of the Exchange Act, limiting liability exposure for these preliminary figures.
Investor Verification Checklist
- Verify the final audited revenue figures for Q4 and full-year 2021 when released in February 2022.
- Confirm the final cash, cash equivalents, and marketable securities balance as of December 31, 2021.
- Review the complete financial statements for details on operating expenses, net income, and debt obligations not included in this preliminary report.
- Assess the commercial launch progress of ONPATTRO, GIVLAARI, and OXLUMO against the updates provided.